Firefly_Gemini-Flash_Make-the-shirt-in-the-photo-white-and-add-my-company-information-from-the-reference-p-873492-1200x670.png

Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment of type 2 diabetes and obesity. But as millions of patients now use these medications, reports of skin hypersensitivity reactions are drawing increased attention from clinicians and patients alike.

If you or a patient is experiencing a rash, hives, or injection site irritation while on a GLP-1 medication, this guide covers everything you need to know.

What Are Skin Hypersensitivity Reactions?

Skin hypersensitivity reactions are immune-mediated responses in which the body overreacts to a substance — in this case, a GLP-1 receptor agonist or one of its inactive ingredients. These reactions range from mild localized irritation to rare but serious systemic allergic responses.

They are distinct from simple side effects like nausea or diarrhea. Skin reactions involve the immune system and can evolve unpredictably, which is why early recognition matters.

What Causes Skin Hypersensitivity Reactions in GLP-1 Medications?

Several mechanisms can trigger skin reactions in patients taking GLP-1 medications:

1. Injection Site Reactions

The most common skin reaction, affecting an estimated 5–20% of patients. Localized redness, swelling, itching, bruising, or nodule formation at the injection site can result from the needle puncturing subcutaneous tissue repeatedly in the same location, the pH or osmolality of the drug formulation irritating local tissue, or a localized immune response to the peptide or excipients (e.g., polysorbate 80).

2. IgE-Mediated (Type I) Hypersensitivity

This is a true allergic reaction where the immune system produces IgE antibodies against the drug or its components. It can manifest as urticaria (hives), angioedema (swelling of deeper tissue layers), or — in rare cases — anaphylaxis. Symptoms typically occur within minutes to hours of administration.

3. Delayed (Type IV) Hypersensitivity

A T-cell-mediated reaction that develops 24–72 hours after exposure. This typically presents as a contact-dermatitis-like rash at or around the injection site and may worsen with repeated exposure.

4. Bullous Pemphigoid

An increasingly documented, serious skin condition linked to certain GLP-1 agents. It causes large, fluid-filled blisters on the skin due to autoantibodies attacking the skin’s basement membrane. The exact mechanism is still under investigation, but immunomodulatory effects of the drug class are suspected.

5. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Rare but serious. DRESS involves a widespread rash, fever, lymphadenopathy, and internal organ involvement. It is thought to be a T-cell-mediated hypersensitivity reaction and typically appears 2–8 weeks after starting a new medication.

6. Lipodystrophy

Repeated injections in the same site can cause lipoatrophy (loss of fat) or lipohypertrophy (excess fat buildup), altering skin texture and drug absorption. While not a traditional allergic reaction, it reflects a localized tissue response to repetitive mechanical and chemical injury.

How Common Are These Reactions?

Injection site reactions (mild) occur in an estimated 5–20% of patients. Urticaria or generalized rash affects 1–5%. Angioedema occurs in under 1%. Bullous pemphigoid is rare, based on case reports and emerging data. Anaphylaxis is very rare (under 0.1%), and DRESS is very rare as well.

Mild injection site reactions are by far the most common and typically resolve on their own. Serious systemic reactions are uncommon but require immediate medical attention.

Are GLP-1 Skin Reactions Dangerous?

Most are not. The majority of patients who experience skin reactions have mild, localized symptoms that improve without medical intervention or with simple management strategies.

However, certain reactions warrant urgent care. Seek emergency care immediately if you notice: throat tightening, difficulty breathing, or wheezing (signs of anaphylaxis); rapid spread of hives across the body combined with dizziness or a drop in blood pressure; widespread blistering of the skin; or fever, facial swelling, or internal organ symptoms alongside a rash (possible DRESS).

Bullous pemphigoid, while not immediately life-threatening, can be debilitating and requires prompt dermatological evaluation. If left untreated, blistering can lead to secondary infections and significant morbidity — particularly in older adults.

How Are GLP-1 Skin Hypersensitivity Reactions Treated?

Mild Injection Site Reactions

Rotate injection sites (abdomen, thigh, upper arm) with each dose. Apply a cool compress after injecting. Use over-the-counter topical hydrocortisone cream to reduce localized inflammation. Oral antihistamines (e.g., cetirizine, loratadine) can relieve itching.

Urticaria and Generalized Rash

Oral antihistamines are first-line treatment. If symptoms persist, a short course of oral corticosteroids may be prescribed. Depending on severity, the prescribing clinician may pause or switch the GLP-1 medication.

Angioedema

Mild angioedema without airway involvement: antihistamines and monitoring. Severe angioedema or any airway compromise: epinephrine (EpiPen), emergency care, and discontinuation of the drug.

Anaphylaxis

Immediate epinephrine injection (IM, lateral thigh), emergency transport, permanent discontinuation of the offending GLP-1 agent, and allergy/immunology evaluation for potential cross-reactivity with other agents in the class.

Bullous Pemphigoid

Dermatology referral is essential. Topical or systemic corticosteroids are the cornerstone of treatment. Immunosuppressants (e.g., dapsone, azathioprine, methotrexate) may be used in refractory cases. The GLP-1 medication is typically discontinued, though the decision should be weighed against the patient’s metabolic needs.

DRESS

Immediate discontinuation of the offending drug, systemic corticosteroids, hospitalization in moderate-to-severe cases, and internal medicine and dermatology co-management.

How to Prevent Skin Hypersensitivity Reactions on GLP-1 Medications

Before Starting Treatment

Disclose your full allergy history to your prescribing clinician, including reactions to other injectable medications or peptide-based drugs.
Review excipient ingredients in the specific formulation — some patients react to inactive ingredients like polysorbate 80 or metacresol rather than the active peptide itself.
Start with a supervised first injection if there is any concern about hypersensitivity history.

Injection Technique

Rotate sites systematically — never inject the same spot twice in a row; use a rotation chart if needed.
Allow the pen to reach room temperature before injecting (10–15 minutes out of the refrigerator) to reduce local irritation.
Pinch the skin gently and inject at the correct angle to ensure subcutaneous — not intramuscular — delivery.
Do not inject into areas of active irritation, redness, bruising, or lipodystrophy.

Ongoing Monitoring

Inspect injection sites after every dose for early signs of reaction.
Keep a symptom log for the first 8–12 weeks of treatment, noting any skin changes, their timing relative to injections, and their location.
Communicate promptly with your healthcare provider about any new or worsening skin symptoms — do not wait until the next scheduled appointment.

For Patients with a Previous Mild Reaction

A clinician may recommend premedication with an antihistamine 30–60 minutes before each injection.
Switching to a different GLP-1 agent with a different formulation may eliminate the reaction if the trigger is an excipient rather than the peptide class itself.
Desensitization protocols are experimental and not standard of care, but may be considered in specialist settings for patients with significant metabolic benefit from the drug.

When Should You Stop Taking a GLP-1 Medication?

Stop the medication and contact your provider if you experience a rash that is rapidly spreading, blistering, or involving mucous membranes; any symptoms of anaphylaxis (airway involvement, hypotension, loss of consciousness); widespread blistering suggestive of bullous pemphigoid; or a rash accompanied by fever, facial swelling, or lymph node enlargement.

For mild injection site reactions alone, you do not need to stop the medication — site rotation and topical care are usually sufficient. Always consult your clinician before making any changes to your medication regimen.

The Bottom Line

Skin hypersensitivity reactions to GLP-1 medications are real but, in the vast majority of cases, manageable. Mild injection site reactions are common and rarely require stopping treatment. Serious systemic reactions — while medically significant — are uncommon.

The key is awareness: patients and clinicians who know what to watch for can catch reactions early, respond appropriately, and make informed decisions about whether to continue, modify, or discontinue treatment. Given the substantial cardiometabolic benefits of GLP-1 medications, the goal is always to keep patients on therapy safely whenever possible.

Frequently Asked Questions

Q: Can I switch to a different GLP-1 medication if I have a skin reaction?
Yes, in many cases. If the reaction is caused by an excipient rather than the GLP-1 peptide itself, switching formulations may resolve it. However, if the reaction is to the peptide class broadly, cross-reactivity is possible. An allergist can help assess this.

Q: How long do injection site reactions typically last?
Most resolve within a few hours to days. If a reaction persists beyond a week or worsens, contact your provider.

Q: Can GLP-1 medications cause eczema to flare?
There is limited evidence that GLP-1 agents directly trigger eczema flares, but the immune modulation and skin barrier disruption at injection sites may worsen pre-existing atopic conditions in some patients.

Q: Is bullous pemphigoid permanent?
Not always. In drug-induced cases, discontinuing the offending medication often leads to remission, though treatment is still required while the blistering is active.

Q: Should I carry an EpiPen if I’m on a GLP-1 medication?
Not routinely. Your clinician will advise you on whether your personal risk profile warrants a prescribed epinephrine auto-injector.

Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health.

Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health

If you’ve been on social media lately and your algorithm has pegged you as someone interested in health, chances are you’ve been flooded with content about peptide therapy. It reminds me of the old Apple commercial — but instead of “There’s an app for that,” it seems like no matter what you’re feeling these days, “There’s a peptide for that.”

Stronger muscles? Cut fat? Younger skin? There’s a peptide stack for all of it. But here’s the question nobody on your TikTok feed is asking: Are peptides actually safe?

As a board-certified physician who prescribes FDA-approved peptides daily, I want to give you an honest, evidence-based answer.

What Are Peptides? (And Are You Already Taking One?)

Before diving into the controversy, let’s define the term. Peptides are short chains of amino acids that act as signaling molecules in the body. They help regulate essential functions like hormone production, immune response, tissue repair, and metabolism. Because they break down in the stomach when taken orally, peptides are generally administered subcutaneously (via injection under the skin) to maximize bioavailability.

Peptides can be naturally occurring — produced by the human body, animals, plants, or microorganisms — or synthetic, meaning created in a laboratory to target specific receptors.

Here’s what surprises many of my patients: they’re already taking peptides and don’t even know it.

Insulin — a peptide that revolutionized diabetes treatment over a century ago
Semaglutide (Ozempic/Wegovy) — an FDA-approved GLP-1 peptide for type 2 diabetes and obesity
Tirzepatide (Mounjaro/Zepbound) — in my clinical opinion, the most effective FDA-approved peptide ever developed

These are all FDA-approved synthetic peptides backed by years of clinical trials demonstrating both safety and efficacy. There are currently approximately 80 FDA-approved peptides, 200 in clinical development, and over 600 in pre-clinical trials. What’s being sold on social media represents a tiny, largely unregulated slice of a much larger scientific space.

The Peptides Being Sold on Social Media: What You’re Actually Being Offered

Here’s a breakdown of the most commonly marketed non-FDA approved peptides you’ll find online and on social media:

For muscle, fat loss, and anti-aging: The Morelin family of peptides (including Ipamorelin and CJC-1295) claim to stimulate the pituitary gland, boost growth hormone, build muscle, and slow aging. Theoretical benefits? Sure. Proven safety data? No.

For skin and collagen (“The Glow Blend”): A combination of BPC-157, TB-500, and GHK-Cu — marketed for anti-inflammatory effects, tissue repair, and increased collagen production.

For joint pain and injury recovery (“The Wolverine Stack”): BPC-157 + TB-500, promoted to accelerate healing of tendons, ligaments, and muscle tissue.

For energy and metabolism: MOTS-c and NAD+ (note: NAD+ is not actually a peptide) are marketed to boost mitochondrial function and metabolic efficiency.

For tanning and libido: Melanotan II, injected to stimulate melanocytes — giving a tan without sun exposure while reportedly increasing libido.

The list goes on. Each of these sounds compelling. But here’s what the influencers selling them aren’t telling you.

Why I Don’t Prescribe Non-FDA Approved Peptides

1. There Is No Safety or Efficacy Data

The most important thing I can tell you is this: anyone claiming these peptides are safe and effective is lying to you — not because they’re necessarily malicious, but because that data simply does not exist.

Most of the peptides being sold on social media were banned by the FDA in September 2023 for presenting “significant safety risks.” They have not undergone the clinical trials required to demonstrate efficacy or safety — short-term or long-term.

The theoretical benefits are real — these peptides do target specific signaling pathways. But so do the theoretical risks:

Growth hormone-stimulating peptides may help build muscle, but they can also accelerate the growth of undiagnosed tumors or precancerous cells.
Melanotan II may darken your skin without sun exposure, but stimulating melanocytes may also increase your risk of melanoma and other skin cancers.

Theoretical benefit without clinical data is not medicine. It’s an experiment.

2. They Are No Longer Being Produced by Credentialed Pharmacies

Before the 2023 FDA ban, some of these peptides could be legally sourced from credentialed compounding pharmacies — the same type of pharmacies that produce GLP-1 medications today. They required a physician’s prescription and were used under medical supervision. I was still reluctant to prescribe them then due to safety concerns, but at least a regulated framework existed.

That framework is gone.

Today, these peptides are produced and sold for “research use only” with labels stating “not for human consumption.” The majority of source material is coming from unregulated manufacturers in China, raising serious concerns about purity, contamination, and dosing accuracy.

Most of these peptides no longer even require a prescription. You can purchase them online by simply clicking a box claiming you’re buying them for research purposes — not to inject into your body.

Prescribing a medication banned by the FDA and labeled “not for human consumption” is, in my view, a direct violation of a physician’s oath to do no harm.

Dr. Q’s Take: My Official Position on Non-FDA Approved Peptides

I view the current non-FDA approved peptide market as an experiment-at-your-own-risk space.

Think of it this way: imagine if Arnold Schwarzenegger had a TikTok account in the 1970s documenting his bodybuilding and anabolic steroid use — before anyone understood the long-term cardiovascular consequences. That’s exactly what’s happening today with FDA-banned peptides, promoted by so-called health experts and wellness influencers.

I don’t promote unproven treatments to generate revenue. I don’t take medical advice from social media influencers. And I don’t experiment with my patients’ health. Without reliable clinical data, it’s nearly impossible to separate cutting-edge medicine from the next healthcare cautionary tale.

If you choose to use non-FDA approved peptides despite these risks, at minimum:

Ask exactly where they are sourced and who manufactures them
Seek supervision from a physician who specializes in the field
Get baseline labs and ongoing monitoring for adverse reactions before and during use

Frequently Asked Questions About Peptide Safety

Q: Are all peptides banned by the FDA?
No. There are approximately 80 FDA-approved peptides, including insulin, semaglutide (Ozempic), and tirzepatide (Mounjaro). The peptides banned in 2023 are specific non-FDA approved compounds like BPC-157, TB-500, and Melanotan II that were being compounded without adequate safety data.

Q: Is BPC-157 safe to use?
BPC-157 has not undergone the clinical trials necessary to establish safety or efficacy in humans. It was banned by the FDA in September 2023 due to significant safety risks. It is also prohibited by the World Anti-Doping Agency (USADA).

Q: Can a doctor legally prescribe non-FDA approved peptides?
No. Because these peptides are banned by the FDA for human use and sold only for “research purposes,” they cannot legally be prescribed by a physician. Any doctor claiming to “prescribe” these substances should raise serious red flags.

Q: What’s the difference between semaglutide and BPC-157?
Both are peptides, but they differ in one critical way: semaglutide (Ozempic/Wegovy) is FDA-approved with extensive clinical trial data demonstrating safety and efficacy. BPC-157 has no such data and was banned by the FDA.

The Bottom Line

The peptide space is real, rapidly evolving, and full of genuine promise. GLP-1 medications like semaglutide and tirzepatide are proof of what happens when peptide science is done right — rigorous research, clinical trials, FDA approval, and physician oversight. Hundreds more peptides are in the pipeline that may one day transform medicine.

But what’s being sold to you on Instagram and TikTok right now is not that. It’s unregulated, unsupervised, and unproven.

Proceed with caution. Stay safe. Stay educated. Stay healthy.

References & Further Reading

Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health.

Article Summary:

The FDA has officially declared the end of the tirzepatide shortage and semaglutide shortage, meaning that brand-name medications like Mounjaro®/Zepbound® (tirzepatide) and Ozempic®/Wegovy® (semaglutide) are now widely available. This decision impacts compounding pharmacies and outsourcing facilities, which were previously allowed to produce copies of these medications under emergency provisions.

How Compounding Pharmacies Continue to Serve Patients with Unique Needs:

The FDA recently declared the shortages of tirzepatide and semaglutide officially resolved, marking a turning point in the availability of these widely used medications for weight management and type 2 diabetes. While this announcement ensures that FDA-approved products like Mounjaro^®/Zepbound^® (tirzepatide) and Ozempic^®/Wegovy^® (semaglutide) are now readily accessible, it also signals a shift in the role of compounding pharmacies and outsourcing facilities. The physicians and pharmacies, which played a critical role during the shortages, are now adapting to continue serving patients with unique healthcare needs through clinically differentiated formulations.

The FDA’s Decision and Its Implications:

The semaglutide and tirzepatide shortages, which began in 2022 due to high demand, initially allowed compounding pharmacies and outsourcing facilities to produce copies of these medications under provisions of Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. ⁴

However, the FDA has determined that by December 2024 for tirzepatide and February 2025 for semaglutide, manufacturers will be able to meet national demand, leading to the removal of these drugs from the shortage list.

As a result, compounding pharmacies and outsourcing facilities will no longer be able to produce copies of these drugs under the emergency provisions.^1, 2, 3

Specifically:

Compounding pharmacies will no longer be able to make copies of semaglutide after April 22, 2025, and tirzepatide after March 19, 2025, unless they can demonstrate a documented clinical difference that addresses specific patient needs, in accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act.
Outsourcing facilities will no longer be able to produce semaglutide after May 22, 2025, and tirzepatide after March 19, 2025.

This regulatory shift means that outsourcing facilities can no longer produce these drugs in any form and compounding pharmacies can no longer produce copies of these drugs unless they provide a documented clinical difference that meets specific patient needs under Section 503A of the Federal Food, Drug, and Cosmetic Act.⁴

Role of Compounding Pharmacies Post-Shortage:

Even as enforcement tightens, compounding pharmacies remain essential for patients who require customized versions of tirzepatide or semaglutide. Here’s how they continue to make a difference:

Differences in Formulations:

Compounding pharmacies can continue to legally produce tirzepatide or semaglutide with modifications that address unique patient needs. For example:

Adding Active Pharmaceutical Ingredients: Some compounded formulations include niacinamide (a form of vitamin B3), which may offer additional metabolic benefits.

Orally Disintegrating Tablets (ODTs): For patients who struggle with injections or have needle phobia, ODTs may provide a convenient alternative delivery method.^4, 8

These modifications are not available in FDA-approved GLP-1 products but may improve treatment adherence and outcomes for certain patients.

Personalized Dosages:

While many commercial products are available in fixed doses, compounded medications can be tailored to provide precise dosages that align with individual medical requirements.

This flexibility is particularly valuable for patients who experience side effects at standard doses or require gradual titration.

To learn more about customized medication dosing book your free consult at:

WWW.GOODHEARTSHEALTH.COM

Challenges Ahead:

Despite their critical role during shortages, compounding pharmacies face increasing scrutiny from regulatory agencies. Both Eli Lilly (maker of Mounjaro®/Zepbound®) and Novo Nordisk (maker of Ozempic®/Wegovy®) have raised concerns about counterfeit or substandard compounded versions of their drugs.^1, ⁸

To address these concerns, compounding pharmacies must continue to prioritize transparency and adherence to legal requirements.

Conclusion:

The resolution of the tirzepatide and semaglutide shortages marks a new chapter in patient care. While FDA-approved products are now widely available, compounding pharmacies remain indispensable for those who require personalized formulations. By offering options like niacinamide-enhanced injections or orally disintegrating tablets, these pharmacies may help ensure that personalized care remains accessible to all patients. As the healthcare landscape evolves, compounding pharmacies will continue to adapt, demonstrating their commitment to meeting unique patient needs while adhering to high standards of safety and quality.

References:

1. https://www.healio.com/news/endocrinology/20241220/fda-confirms-end-of-tirzepatide-shortage

2. https://www.bipc.com/fdas-removal-of-semaglutide-and-the-evolving-tirzepatide-decisions-what-compounders-need-to-know

3. https://www.healio.com/news/endocrinology/20250221/fda-removes-semaglutide-from-drug-shortage-list

4. https://www.techtarget.com/pharmalifesciences/feature/Understanding-tirzepatide-compounding-restrictions

5. https://time.com/6301552/weight-loss-drugs-compounding-pharmacies/

6. https://ncpa.org/newsroom/qam/2025/03/13/fda-ends-compounding-discretion-tirzepatide-maintains-discretion

7. https://www.mwe.com/insights/semaglutide-shortage-resolved/

8. https://www.medpagetoday.com/special-reports/exclusives/111577

9. https://www.yahoo.com/lifestyle/millions-of-people-are-taking-compounded-weight-loss-drugs-now-theyre-about-to-disappear-202621562.html

10. https://www.blogs.joinmochi.com/blogs/tirzepatide-vs-semaglutide

11. https://qz.com/ozempic-glp1-shortage-compounded-tirzepatide-1851769293

12. https://www.fiercepharma.com/pharma/compounders-sue-fda-again-over-declaring-end-shortage-novos-semaglutide

13. https://abcnews.go.com/GMA/Wellness/compound-versions-weight-loss-drugs-longer-fda-rules/story?id=119665010

14. https://www.drugs.com/medical-answers/you-tirzepatide-compounding-pharmacy-3575862/

15. https://newdrugloft.com/tirzepatide-injections-an-alternative-to-compounded-semaglutide/

16. https://www.cbsnews.com/news/fda-declares-end-to-wegovy-and-ozempic-shortage/

17. https://www.pharmacytimes.com/view/fda-ends-semaglutide-shortage-listing-contributing-to-ongoing-legal-challenges

18. https://sesamecare.com/blog/semaglutide-shortage

Medically authored by Dr. Mario Quiros, MD — Diplomate of the American Board of Obesity Medicine | Good Hearts Health | Last medically reviewed: June 2026

“How many milligrams do I take?” and “How do I measure that in units on a syringe?” — these are questions I answer every single day in my weight loss practice. If you’re taking compounded semaglutide or tirzepatide for weight loss, understanding your exact dose is critical for both safety and results.

This complete semaglutide and tirzepatide dosing guide covers everything: how doses are measured in milligrams, how to convert mg to mL, and exactly how many units to draw on an insulin syringe — including the specific dosing schedules we use at Good Hearts Health.

What Are Semaglutide and Tirzepatide?

Semaglutide and tirzepatide are GLP-1 receptor agonists (tirzepatide also targets GIP receptors) approved for weight management and type 2 diabetes. Compounded versions of both medications are prescribed by weight loss physicians and dosed via weekly subcutaneous injection using a standard U-100 insulin syringe.

What Is Your Semaglutide or Tirzepatide Dose in Milligrams?

Both Semaglutide and Tirzepatide are dosed in milligrams (mg). You should always start on the lowest dose and titrate upward based on three key factors:

1. How Long Have You Been at Your Current Dose?

It is recommended that you stay at each dose for a minimum of 4 weeks before increasing. This allows your body to acclimate to the medication and prevents side effects that can occur from increasing the dose too quickly.

2. Are You Experiencing Side Effects?

If you are having side effects at your current dose, do not increase your dosage until those side effects have resolved. Increasing too soon will likely make them worse.

3. Are You Losing Weight?

I recommend a consistent weight loss of 1.5 to 2 lbs per week as a target. If you are hitting this consistently, there is no need to increase your dose. I only recommend a dosage increase if weight loss falls below this threshold or you hit a plateau.

How to Convert Your Semaglutide or Tirzepatide Dose from mg to Units

Every compounded medication has a concentration expressed in mg/mL — meaning how many milligrams of the drug are dissolved in 1 mL of liquid. Every 1 mL equals 100 units on an insulin syringe.

Once you know your concentration and your desired dose in mg, you can calculate exactly how many units to draw up.

The Formula: mg to mL

Desired dose (mg) ÷ Concentration (mg/mL) = Volume to inject (mL)

Example — Semaglutide starting dose:
0.25 mg ÷ 5 mg/mL = 0.05 mL

Converting mL to Units on a Syringe

To convert mL to units, multiply by 100:

0.05 mL × 100 = 5 units

So a 0.25 mg dose of Semaglutide (5 mg/mL concentration) = 5 units on an insulin syringe.

How to Calculate Your Dose in mg If You Only Know Your Units

This is one of the most common questions I get from patients who are new to my practice or transferring from another provider. Many patients are told how many units to inject but don’t know what that equals in milligrams.

The Formula: Units to mg

(Units ÷ 100) × Concentration (mg/mL) = Dose in mg

Example — Tirzepatide patient taking 44 units at 17 mg/mL:
(44 ÷ 100) × 17 mg/mL = 7.5 mg

So 44 units of Tirzepatide at 17 mg/mL = 7.5 mg of the medication.

Good Hearts Health Dosing Schedules

The following are the dosing guidelines I use for patients at Good Hearts Health, based on the specific concentrations of Semaglutide and Tirzepatide we currently prescribe.

Starting dose for Semaglutide: 0.25 mg weekly = 5 units (0.05 mL) on the insulin syringe provided.
Starting dose for Tirzepatide: 2.5 mg weekly = 15 units (0.15 mL) on the insulin syringe provided.

Semaglutide Dosing Schedule (5 mg/mL Concentration)

Dose (mg)	Units on Syringe	Duration
0.25 mg	5 units	2–4 weeks
0.5 mg	10 units	4 weeks
1.0 mg	20 units	4 weeks
1.7 mg	34 units	4 weeks
2.4 mg	48 units	4 weeks

Tirzepatide Dosing Schedule (17 mg/mL Concentration)

Dose (mg)	Units on Syringe	Duration
2.5 mg	15 units	2–4 weeks
5.0 mg	30 units	4 weeks
7.5 mg	45 units	4 weeks
10.0 mg	60 units	4 weeks
12.5 mg	74 units	4 weeks
15.0 mg	88 units	4 weeks

Important reminder: The goal is always the lowest effective dose. If you are tolerating the medication well and losing 1.5–2 lbs per week consistently, there is no reason to increase your dose. Only consider increasing after 4 weeks at your current dose if weight loss has plateaued.

Frequently Asked Questions About Semaglutide and Tirzepatide Dosing

Q: How do I know if my Semaglutide dose is working?
A consistent weight loss of 1.5–2 lbs per week indicates your dose is effective. If you are losing weight steadily, stay at your current dose — more is not always better.

Q: What happens if I increase my dose too quickly?
Increasing your dose before your body has acclimated increases the risk of side effects including nausea, vomiting, and GI discomfort. Always stay at each dose for at least 4 weeks.

Q: Can I calculate my Tirzepatide dose in units at home?
Yes. Use this formula: (Units ÷ 100) × Concentration (mg/mL) = Dose in mg. You will need to know the concentration of your specific medication vial.

Q: What concentration of Semaglutide does Good Hearts Health prescribe?
Good Hearts Health prescribes Semaglutide at 5 mg/mL and Tirzepatide at 17 mg/mL. If you are using medication from a different provider, confirm your concentration before calculating your dose.

Q: Is Tirzepatide dosed differently than Semaglutide?
Yes. While both medications are dosed in mg, Tirzepatide has a different concentration and dosing schedule. Always follow the schedule specific to your medication and concentration.

Q: How many units is 0.25 mg of semaglutide?
At a concentration of 5 mg/mL (the concentration used at Good Hearts Health), 0.25 mg of semaglutide equals 5 units on an insulin syringe. If your vial has a different concentration, divide 0.25 by your concentration and multiply by 100.

Q: How many units is 2.5 mg of tirzepatide?
At a concentration of 17 mg/mL (the concentration used at Good Hearts Health), 2.5 mg of tirzepatide equals approximately 15 units. Concentrations vary by pharmacy — always verify your specific vial.

Q: What syringe should I use for compounded semaglutide or tirzepatide?
Use a standard U-100 insulin syringe. Every 1 mL on a U-100 syringe equals 100 units, which is the basis for all unit calculations in this guide.

Final Thoughts from Dr. Q

One of my mentors used to tell me, “Life is complicated, but medicine makes sense!” I hope this guide on Semaglutide and Tirzepatide dosing has made things a little clearer. Understanding your dose — in mg, mL, and units — puts you in control of your weight loss journey and helps you use these powerful medications safely and effectively.

If you have any questions about your specific dosing, please don’t hesitate to reach out to our team at Good Hearts Health.

Additional Resources

Medically authored by Dr. Mario Quiros, MD. Diplomate of the American Board of Obesity Medicine. Owner and Operator of Good Hearts Health.

GOOD HEARTS HEALTH

GOOD HEARTS HEALTH

BLOGS

©2023 by Good Hearts Health.

What Are Skin Hypersensitivity Reactions?

What Causes Skin Hypersensitivity Reactions in GLP-1 Medications?

1. Injection Site Reactions

2. IgE-Mediated (Type I) Hypersensitivity

3. Delayed (Type IV) Hypersensitivity

4. Bullous Pemphigoid

5. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

6. Lipodystrophy

How Common Are These Reactions?

Are GLP-1 Skin Reactions Dangerous?

How Are GLP-1 Skin Hypersensitivity Reactions Treated?

Mild Injection Site Reactions

Urticaria and Generalized Rash

Angioedema

Anaphylaxis

Bullous Pemphigoid

DRESS

How to Prevent Skin Hypersensitivity Reactions on GLP-1 Medications

Before Starting Treatment

Injection Technique

Ongoing Monitoring

For Patients with a Previous Mild Reaction

When Should You Stop Taking a GLP-1 Medication?

The Bottom Line

Frequently Asked Questions

What Are Peptides? (And Are You Already Taking One?)

The Peptides Being Sold on Social Media: What You’re Actually Being Offered

Why I Don’t Prescribe Non-FDA Approved Peptides

1. There Is No Safety or Efficacy Data

2. They Are No Longer Being Produced by Credentialed Pharmacies

Dr. Q’s Take: My Official Position on Non-FDA Approved Peptides

Frequently Asked Questions About Peptide Safety

The Bottom Line

References & Further Reading

Article Summary:

How Compounding Pharmacies Continue to Serve Patients with Unique Needs:

The FDA’s Decision and Its Implications:

Role of Compounding Pharmacies Post-Shortage:

Differences in Formulations:

Personalized Dosages:

Challenges Ahead:

Conclusion:

References:

What Are Semaglutide and Tirzepatide?

What Is Your Semaglutide or Tirzepatide Dose in Milligrams?

1. How Long Have You Been at Your Current Dose?

2. Are You Experiencing Side Effects?

3. Are You Losing Weight?

How to Convert Your Semaglutide or Tirzepatide Dose from mg to Units

The Formula: mg to mL

Converting mL to Units on a Syringe

How to Calculate Your Dose in mg If You Only Know Your Units

The Formula: Units to mg

Good Hearts Health Dosing Schedules

Semaglutide Dosing Schedule (5 mg/mL Concentration)

Tirzepatide Dosing Schedule (17 mg/mL Concentration)

Frequently Asked Questions About Semaglutide and Tirzepatide Dosing

Final Thoughts from Dr. Q

Additional Resources